INTRODUCTION
Strong centrally acting analgesics (e.g., opioids) are gaining acceptance for use in the management of non-malignant, chronic pain [1] [2] [3] . In addition to relieving pain, goals of long-term analgesic therapy are to allow patients to maintain their independence and stay active [4] . The ability to drive safely is a key component of daily living [4] . Studies have shown that patients on stable doses of opioid analgesics may be able to drive safely based on individual evaluations [5] [6] [7] [8] [9] [10] . However, medications with lopioid receptor agonist activity may adversely affect patients' cognitive and psychomotor performance, particularly during titration when dose changes occur [11] [12] [13] [14] [15] .
Tapentadol is a centrally acting analgesic with two mechanisms of action, l-opioid receptor agonism and noradrenaline reuptake inhibition [16, 17] . Tapentadol prolonged release (PR) is approved in Europe for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics [18] , and in the United States (tapentadol extended release) for the management of moderate to severe, chronic pain, and neuropathic pain associated with diabetic peripheral neuropathy in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time [19] . In a randomized, controlled phase 3 study [20] , tapentadol PR (100-250 mg twice daily [bid] ) was associated with a lower incidence of dizziness and fewer discontinuations due to nervous system side effects than oxycodone controlled release (20-50 mg bid). The lower incidence of nervous system side effects with tapentadol compared with oxycodone may be related to the contribution of noradrenaline reuptake inhibition to its analgesic activity [17, 20] .
This multicenter, open-label, phase 3b trial [24] . The test system includes a color monitor (and/or projector), speakers, a special keyboard with joysticks, steering wheels, two pedals, two peripheral displays with a light diode matrix, and the software. The test system provides an empirically validated model (called a ''neuronal network''), which uses test scores to predict results of a standardized driving test.
The model enables subjects to be assigned to an overall classification of driving-specific ability (specified as the global judgment of driving ability) based on the following six battery tests: the adaptive matrices test, the cognitrone, the tachistoskopic traffic conception test, the reaction test, the determination test, and the peripheral perception test. The global judgment of driving ability was used to determine whether a subject's psychomotor performance and cognition fulfill the criteria of driving a car safely. A binary (yes/no classification) outcome was created for each of the individual performance tests, with a successful outcome (i.e., positive response) defined as a score that was C16th percentile on the respective test (based on a normal distribution in healthy subjects) [10] . For the global judgment of driving ability, subjects who were considered fit to drive fell into one of the following three subgroups: subjects with adequate drivingrelated ability (score C16th percentile on all 6 battery tests), subjects with adequate driving ability and performance deficits that could be compensated (score \16th percentile on C1 of the battery tests, but performance in other areas is sufficient to compensate for performance deficits), or subjects with performance deficits that could be compensated to a limited extent Pain intensity was assessed on an 11-point numerical rating scale-3 (NRS-3; recalled average pain intensity score during the last 3 days from 0 = ''no pain'' to 10 = ''pain as bad as you can imagine'') at the enrollment and final visits. At the time of the test, patients also reported their current pain intensity (11-point NRS).
Safety evaluations included treatmentemergent adverse event (TEAE) reporting, vital sign evaluations, physical examinations, and a driving history questionnaire. All adverse events that occurred between the enrollment and final visits were defined as TEAEs. Vital signs, including systolic and diastolic blood pressure, pulse rate, and respiratory rate, were measured at the enrollment, test, and final visits. For patients with a valid driving license, the driving history questionnaire assessed the year of passing the driving test, class of driving license, approximate distance driven in the last year, and whether the patient felt fit to drive.
STATISTICAL ANALYSES
Based on exploratory studies of the effects of opioids on driving ability [9, 10] 
RESULTS

Patients
The safety population included 38 patients who were enrolled and completed the trial. Demographic data for those patients are summarized in Table 1 . The per protocol population (patients who completed all 6 battery tests of the Vienna Test System-Traffic Plus) included 35 patients. Three patients in the safety population were excluded from the per protocol population because of major protocol violations. One of those patients had a history of alcohol abuse and impaired hepatic function due to formal alcohol abuse, both of which violated the study exclusion criteria. One patient took a prohibited medication (benzodiazepine), and one patient took tapentadol IR on the day of the test visit.
In the safety population, 86.8% (33/38) of patients held a valid driving license, and 78.9% 
Treatment Exposure
In the safety population, the mean (SD) duration of tapentadol PR exposure in the current study was 23.9 (7.92) days (range classified as fit to drive, 7 had adequate driving ability, 11 had performance deficits that could be compensated, and 5 had performance deficits that could be compensated to a limited extent. The five patients with performance deficits that could be compensated to a limited extent were classified as fit to drive because their relevant scores as defined in a previous study [10] for each single test (cognitrone, tachistoskopic traffic conception, and determination) were C16th percentile.
Twelve (34.3%) patients were classified as not fit to drive. Of those patients, three had inadequate driving ability, seven had noncompensable performance deficits, and two had performance deficits that could be compensated to a limited extent. The two patients with performance deficits that could be compensated to a limited extent were classified as not fit to drive because their scores for C1 single test (cognitrone, tachistoskopic traffic conception, and/or determination) were \16th percentile [10] .
Overview of Individual Test Results
Individual test results from the Vienna Test System-Traffic Plus are summarized in Table 2 .
More than 70% of patients were classified as having a successful outcome for the cognitrone, 
Exploratory Analyses of Variables Affecting Global Judgment
Exploratory subgroup analyses were conducted to determine the impact of IQ, educational level, age, daily dose of tapentadol PR, current pain intensity, and distance driven in the previous year on global judgment (Table 3) .
Patients with an IQ C 85 generally performed better in the test system and were more fit to drive than patients with an IQ\85, but the differences were not statistically significant 
Efficacy-Related Parameter
Pain scores on the 11-point NRS remained relatively unchanged from the start to the end of the trial, indicating that the pain relief achieved during the previous phase 3b studies [22, 23] was maintained with continued tapentadol PR treatment during this trial.
Pain intensity scores are summarized in Table 4 . The driving ability of patients under stable tapentadol PR treatment in this trial is comparable to that observed in previous studies in patients under stable treatment with transdermal fentanyl [10] or transdermal buprenorphine [9] . Results of those studies [9, 10] showed that the driving ability of patients under stable transdermal treatment with fentanyl or buprenorphine was non-inferior to that of healthy, untreated subjects, indicating that patients on stable treatment with strong opioids might be able to drive safely based on individual evaluations. The percentage of patients (34.3%) in the current trial with an individual result C16th percentile for 5 key tests (cognitrone, tachistoskopic traffic conception, determination, vigilance, and two-hand coordination tests) was comparable to or higher than the percentage of patients with an individual result C16th percentile in those previous studies with transdermal fentanyl [10] or transdermal buprenorphine [9] .
Exploratory subgroup analyses showed that educational level, the total daily dose of tapentadol PR, and current pain intensity at Analgesic therapy for the management of non-malignant, chronic pain may not only provide adequate pain relief, but may also allow patients to preserve their independence and stay active, including maintaining the ability to drive safely [4] . Pain of high intensity can reduce cognitive capacity and impair driving performance [28, 29] ; when pain intensity is reduced, patients may be better able to focus on driving. Consistent with results of the current study, numerous studies have shown that patients on stable doses of opioid analgesics may be able to drive safely based on individual evaluations [5] [6] [7] [8] [9] [10] .
Epidemiologic evidence also indicates that patients on stable doses of opioid analgesics are not at an increased risk for being in fatal or non-fatal car accidents [6] .
CONCLUSION
Results of this trial based on a global judgment parameter suggest that most patients under treatment with a stable dose of tapentadol PR (50-250 mg bid) for the management of severe chronic pain would be able to drive. Outcomes of the current study are overall consistent with earlier studies [9, 10] , supporting driving ability for patients under stable treatment with strong opioids. Methodological limitations (e.g., lack of pre-study measurement of driving ability) need to be taken into account when interpreting these results. Individual responses to treatment with tapentadol PR may vary, and individual driving assessments for patients who are prescribed tapentadol should be considered in cases of uncertainty for an individual patient (e.g., patients with additional risk factors, such as impaired cognitive or psychomotor performance). In general, the safety profile of tapentadol PR observed in this study was consistent with that observed in previous multiple-dose studies of tapentadol PR in patients with non-malignant, chronic pain [20, 22, 23, [30] [31] [32] .
